The FirstTake Podcast – 16 September 2021

In this episode editors Virginia Li, Michael Flanagan and Simon King discuss AbbVie’s deal to in-license an investigational gene therapy for age related macular degeneration from Regenxbio, an increasing focus on mRNA vaccines and therapeutics among Chinese biotech companies and why a new academic study may pose further challenges for Biogen’s Aduhelm.

Please subscribe, like and share and most importantly, thanks for listening.

Listen on Apple podcastsSpotify or Google

To read more ViewPoints articles, click here.